Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ascendis Pharma A (ASND) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Ascendis Pharma A (ASND) over the last 14 years, with Q4 2025 value amounting to $4377.2.

  • Ascendis Pharma A's Shares Outstanding (Weighted Average) fell 3727.07% to $4377.2 in Q4 2025 from the same period last year, while for Dec 2025 it was $4377.2, marking a year-over-year decrease of 3727.07%. This contributed to the annual value of $4249.2 for FY2025, which is 3910.54% down from last year.
  • Ascendis Pharma A's Shares Outstanding (Weighted Average) amounted to $4377.2 in Q4 2025, which was down 3727.07% from $3764.4 recorded in Q3 2025.
  • Over the past 5 years, Ascendis Pharma A's Shares Outstanding (Weighted Average) peaked at $62.7 million during Q4 2021, and registered a low of $1411.3 during Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $6.0 million, with a median of $4457.9 in 2021.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first skyrocketed by 7575.09% in 2022, then plummeted by 9998.39% in 2023.
  • Ascendis Pharma A's Shares Outstanding (Weighted Average) (Quarter) stood at $62.7 million in 2021, then dropped by 8.7% to $57.2 million in 2022, then plummeted by 99.98% to $9199.3 in 2023, then dropped by 24.15% to $6977.9 in 2024, then crashed by 37.27% to $4377.2 in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $4377.2 for Q4 2025, versus $3764.4 for Q3 2025 and $2513.0 for Q2 2025.